Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2019, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.
Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 12, 14, 13, 40, 8 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 5 molecules, respectively.
Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
Introduction
Pulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Therapeutics Development
Pulmonary Arterial Hypertension - Therapeutics Assessment
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development
Pulmonary Arterial Hypertension - Drug Profiles
Pulmonary Arterial Hypertension - Dormant Projects
Pulmonary Arterial Hypertension - Discontinued Products
Pulmonary Arterial Hypertension - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Pulmonary Arterial Hypertension, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Aadi Bioscience Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Abivax SA, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Acceleron Pharma Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Actelion Pharmaceuticals Ltd, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Aerogen Ltd, H2 2019
Pulmonary Arterial Hypertension - Pipeline by AI Therapeutics, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Altavant Sciences Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Apollo Therapeutics LLC, H2 2019
Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Aqualung Therapeutics Corp, H2 2019
Pulmonary Arterial Hypertension - Pipeline by ATXA Therapeutics Ltd, H2 2019
Pulmonary Arterial Hypertension - Pipeline by AVEO Oncology Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Bayer AG, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca SA, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Biogen Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Bristol-Myers Squibb Co, H2 2019
Pulmonary Arterial Hypertension - Pipeline by C4X Discovery Holdings Plc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Camurus AB, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Capricor Therapeutics Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Celsion Corp, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Celtaxsys Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Chiesi Farmaceutici SpA, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Complexa Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Denovo Biopharma LLC, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Co, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Excubio Pharmaceuticals Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by GenThera Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by GEXVal Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Gmax Biopharm Ltd, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Gossamer Bio Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Insmed Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Insys Therapeutics Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by INVENT Pharmaceuticals Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Japan Tobacco Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Liquidia Technologies Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by LTT Bio-Pharma Co Ltd, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Martin Pharmaceuticals Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Merck & Co Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co Ltd, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Mifcare, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Morphogen-IX Ltd, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Nissan Chemical Corp, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Northern Therapeutics Inc, H2 2019
Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2019
List of Figures
Number of Products under Development for Pulmonary Arterial Hypertension, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
